NCT02772497View on ClinicalTrials.gov

3 Month Outcome of Ziv-aflibercept for DME

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Diabetic Macular Edema
Interventions
DRUG

Ziv aflibercept

Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks

All Listed Sponsors
lead

Marashi Eye Clinic

OTHER

NCT02772497 - 3 Month Outcome of Ziv-aflibercept for DME | Biotech Hunter | Biotech Hunter